Comment on: Evidence of innate lymphoid cell redundancy in humans
To the Editor: A 2016 study by Vély et al. suggests that innate lymphocytes, including innate lymphoid cells (ILCs) and natural killer (NK) cells, are dispensable in the control of human disease, at least in the presence of functioning adaptive immunity and under modern living conditions 1 . Their conclusions are based on cohort studies of patients with severe combined immune deficiency (SCID) due to mutations in the gene encoding the tyrosine kinase JAK3 (JAK3) or the gene encoding the common γ -chain cytokine receptor subunit IL-2Rγ (IL2RG) who had an extremely low or undetectable number of ILCs and NK cells after nonmyeloablative allogeneic hematopoietic stem cell transplantation (HSCT) 1 . These findings are important additions to the literature, and investigation of such rare patient populations with long-term follow-up (up to 39 years) is to be commended.
As noted in the accompanying News and Views by Weinkove et al., however, limitations of the study include the small sample size, the limited number of tissue samples with which to investigate resident ILCs, and the suggestion of infectious susceptibility with a lack of innate lymphocytes, with almost half of patients having infection with human papilloma virus (HPV) 2 . Despite this, we have become aware of an emerging viewpoint in the field that NK cells are not required for health in an otherwise immunocompetent patient, on the basis of the findings from this single study. Here, we respectfully offer additional evidence that human NK cells are an essential, non-redundant component of the human immune system.
Although there are over 50 primary immunodeficiencies that affect NK cells, the most informative are NK cell deficiencies (NKDs), in which NK cells are the main immunological defense affected 3 . A common feature of NKD is severe viral infection and malignancy, and many affected patients with NKD die in young adulthood of severe infection with herpesvirus despite intact function of T cells and B cells. At present, the reported genetic causes of NKD include mutations in the following seven genes: FCGR3A, GATA2, GINS1, IRF8, MCM4 and RTEL1 (reviewed in ref.
3 ) and MCM10 (ref. 4 ). 5, 6 . Infection with human cytomegalovirus (HCMV) induces the differentiation of 'adaptive' NK cells with enhanced functionality and distinct epigenetic profiles 7 . The population expansion of HCMV-adapted NK cells in humans in response to other infections provides indirect evidence that these cells have a role in early host defense. Epidemiologic links among combinations of NK cell killer immunoglobulin receptor (KIR) and major histocompatibility complex haplotypes and the risk or severity of infection with hepatitis C virus or human immunodeficiency virus provide further evidence of the importance of an NK cell response to viral infection 8, 9 . Tumor immunosurveillance by NK cells has been well documented in the mouse, and in humans, this is highlighted by a prospective study correlating decreased cytotoxic capacity of NK cells with an increased incidence of cancer 10 . Direct evidence of anti-tumor effects of NK cells in humans has been provided by a multitude of studies demonstrating anti-leukemia effects of NK cells in the context of mismatched HSCT and allogeneic adoptive immunotherapy 5 . Finally, for most aspects of experimental immunology, context matters. The Vély study provides evidence of innate lymphocyte redundancy with adaptive immunity in humans in a very specific context: genetically immunodeficient children who underwent treatment with non-myeloablative allogeneic HSCT that resulted in a donor or chimeric immune system 1 . These patients received intensive medical surveillance after HSCT that included broad anti-microbial prophylaxis for 6-12 months, life-long immunoglobulin replacement in many patients (half of this cohort), and enhanced surveillance for and evaluation of infection and/or fever, relative to that of the general population. Thus, it is challenging to clinically generalize this unique patient population to the average human living under natural conditions, even in developed countries. The clinical results report selected infections, with 8 of 18 (44%) having common warts, while more clinically important events include severe infection with human papilloma virus (HPV) (11%), ear-nose-throat infection (17%), diarrhea (11%) and respiratory sequelae (11%). Although these problems are not considered indicative of disease susceptibility, 7 of the 18 (39%) patients with SCID and deficiency in the common γ -chain or JAK3 experienced at least one of these clinically important events, compared with 0 of 8 (0%) of the control patients undergoing HSCT for other types of SCID, leukemia, or aplastic anemia with complete donor chimerism. Moreover, late-onset cutaneous infection with HPV has been reported in common γ -chain-deficient patients with SCID after HSCT 11, 12 . One study found that the risk of severe infection with HPV in patients who did not receive conditioning correlated with a decreased number and cytotoxic function of NK cells, which was not seen in patients with SCID (those with mutations in JAK3, IL2RG or CD247 (which encodes the invariant signaling protein subunit CD3ζ )) who received myeloablative preparative regimens and had a normal number of NK cells, which would suggest that NK cells (and potentially other ILCs) function in controlling viral infection after transplantation 11 . In contrast, an earlier study observed low NK cell counts in both HPV-positive and HPV-negative common γ chain-or Jak3-deficient patients with SCID after HSCT (with and without conditioning), and no difference among those groups in NK cell cytotoxicity 12 . In summary, while the findings of Vély et al. 1 are provocative, we contend they should be used to generate new hypotheses that will require extensive further study, rather than to define a definitive conclusion about the redundancy of NK cells and ILCs in humans. As discussed below, there are at least six pieces of information to be considered for assessment of the in vivo function of NK cells.
The analysis of primary immunodeficiencies is key for identification of the roles of cells and molecules in immunity. So far, and as described by Orange et al. 1 , there are seven reported inborn errors that lead to NK cell deficiencies (NKDs). The genes involved are GATA2, MCM4, GINS1, MCM10, IRF8, RTEL1 and FCGR3A. However, none of these genes are expressed exclusively in NK cells. More notably, although NKD is present in these patients, many cells of the immune system are affected. The consequences of the mutations are by no means restricted to NK cells. Thus, even if NK cells contribute to the clinical manifestations of the NKD, they are unlikely to be the only immune cells contributing to the disease. In deficiency in the transcription factor GATA2, all myeloid lineages are affected, as are B cells and T cells 3 . Deficiency in GINS1, MCM4 or MCM10 affects DNA replication; consequently, a defect in the gene encoding any of these molecules affects proliferative cells, as reported for neutrophils in GINS1-deficient patients 4, 5 . T cell functions, which are heavily dependent on proliferation, could not be robustly tested in these three cases, which precludes the claim that these conditions could be considered pure NKDs. IRF8 is a major transcription factor for myeloid-cell differentiation, and IRF8 deficiency is associated with a deficiency in dendritic cells 6 . RTEL1 deficiency is a disease that results in abnormal telomeres, which affects NK cells, B cells, T cells and myeloid cells 7 . In deficiency in the immunoglobulin receptor Fcγ RIIIa (encoded by FCGR3A), NK cells are present but NK cell cytotoxicity is diminished, whereas antibody-dependent cellmediated cytoxicity is, surprisingly, intact 8 . Furthermore, FCGR3A is also expressed by subsets of monocytes and macrophages. Thus, in the absence of convincing evidence of selective NKD in humans, it is impossible to draw unequivocal conclusions about the role of NK cells in immunity from the analysis of these clinical conditions.
There is no doubt that NK cells participate in immunity to infection with cytomegalovirus (CMV). Experiments with mice have provided a clear demonstration of this role 9 . Nevertheless, the long-term analysis (up to 39 years) of patients with SCID who had received HSCT revealed that they did not develop symptomatic infections with CMV 2 . This is one of the key messages of our report. The fact that we did not observe an increased incidence of cancer in our cohort of patients with SCID who had received HSCT 2 does not rule out the possibility of a role for NK cells in the control of tumors, which is a feature of their biological function. Functional redundancy with other cells in tumor immunosurveillance might be operating here as well. In addition, we reemphasize here, much as we did in our original report 2 , that our cohort was inadequate for addressing the involvement of NK cells in tumor immunosurveillance: the cohort was too small and the time of follow-up was insufficient to properly analyze this possibility. Of note, the previous epidemiological study mentioned by Orange et al. 1 that addressed the correlation between blood NK cell activity and cancer incidence did not look at T cell activity as a possible correlate of risk of cancer 11 . We cannot agree with Orange et al. when they suggest that the occurrence of infection
